Showing results (141-150 of 224) with videos related to
Sort By:
Pageof 23
British Journal of Clinical Pharmacology|May 25, 2013
The effect of Echinacea purpurea on the pharmacokinetics of docetaxelAndrew K L Goey, Irma Meijerman, Hilde Rosing, et al.Analytical Biochemistry|December 5, 2003
Development and validation of a method to determine the unbound paclitaxel fraction in human plasmaH J G Desirée van den Bongard, E Marleen Kemper, Olaf van Tellingen, et al.Investigational New Drugs|March 29, 2016
Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparisonAnne-Charlotte Dubbelman, Cynthia M Nijenhuis, Robert S Jansen, et al.Molecular Pharmaceutics|November 3, 2021
P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor NiraparibMargarida L F Martins, Nancy H C Loos, Sümeyra Mucuk, et al.Cancer Chemotherapy and Pharmacology|September 22, 2006
Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancerJan H Beumer, Jeany M Rademaker-Lakhai, Hilde Rosing, et al.Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|May 27, 2008
A sensitive assay for the quantitative analysis of vinorelbine in mouse and human EDTA plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometryCarola W N Damen, Hilde Rosing, Matthijs M Tibben, et al.Therapeutic Drug Monitoring|January 30, 2022
Everolimus Concentration in Saliva to Predict Stomatitis: A Feasibility Study in Patients with CancerLaura Molenaar-Kuijsten, Remy B Verheijen, Bart A W Jacobs, et al.Cancer Chemotherapy and Pharmacology|March 27, 2002
Population pharmacokinetics of the novel anticancer agent KRN7000Mirjam Crul, Ron A Mathôt, Giuseppe Giaccone, et al.The Journal of Pharmacy and Pharmacology|January 8, 2014
The effect of complementary and alternative medicines on CYP3A4-mediated metabolism of three different substrates: 7-benzyloxy-4-trifluoromethyl-coumarin, midazolam and docetaxelKim D Mooiman, Roel F Maas-Bakker, Jeroen J M A Hendrikx, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2009
Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatmentJurjen S Lagas, Robert A B van Waterschoot, Vicky A C J van Tilburg, et al.Pageof 23